Table 4. Characteristics of the patients... | American Society of Hematology

Table 4.

Characteristics of the patients having developed a second primary neoplasm in the H90-NM trial

Arm	Sex, age, y, and clinical stage at HD diagnosis	Time from completion of therapy to tumor diagnosis, mo	Type of malignancy	Tumor developed in an irradiated area	Survival from tumor diagnosis, mo
Hematologic malignancies
A	M, 25, IIA	68	Myelodysplasia	No	55
A	M, 38, IA	106	Chronic myelomonocytic leukemia	No	12
A	M, 38, IIIA	77	Acute nonlymphocytic leukemia	No	23*
A	M, 39, IIA	64	Non-Hodgkin lymphoma	No	30*
A	M, 43, IIA	32	Acute nonlymphocytic leukemia	No	40
A	M, 45, IIA	75	Non-Hodgkin lymphoma	No	20
A	M, 55, IIA	23	Non-Hodgkin lymphoma	Cervical	70
A†	F, 62, IIA	3	Non-Hodgkin lymphoma	No	54*
E	M, 65, IIA	51	Non-Hodgkin lymphoma	No	32
Solid tumors
A	M, 32, IA	23	Malignant melanoma	No	100
A†	F, 42, IIA	2	Breast	Mediastinal	56*
A	M, 49, IIA	44	Esophagus	Mediastinal	3*
A	M, 58, IIA	107	Lung	No	1*
A	F, 59, IIA	38	Breast	Mediastinal	44
A‡	M, 60, IIA	38	Bladder	No	9*
A	M, 64, IA	67	Leiomyosarcoma	Axillary	20*
A	M, 65, IIA	61	Colon	No	10*
E	F, 18, IIA	85	Thyroid	Mediastinal	24
E	F, 23, IIA	112	Glioma	No	3
E	F, 39, IIA	87	Breast	Mediastinal	17
E	M, 46, IIA	105	Lung	Mediastinal	7*
E	M, 46, IIIB	56	Larynx	Cervical	8*
E	M, 50, IIIB	97	Lung	Mediastinal	24*

Arm	Sex, age, y, and clinical stage at HD diagnosis	Time from completion of therapy to tumor diagnosis, mo	Type of malignancy	Tumor developed in an irradiated area	Survival from tumor diagnosis, mo
Hematologic malignancies
A	M, 25, IIA	68	Myelodysplasia	No	55
A	M, 38, IA	106	Chronic myelomonocytic leukemia	No	12
A	M, 38, IIIA	77	Acute nonlymphocytic leukemia	No	23*
A	M, 39, IIA	64	Non-Hodgkin lymphoma	No	30*
A	M, 43, IIA	32	Acute nonlymphocytic leukemia	No	40
A	M, 45, IIA	75	Non-Hodgkin lymphoma	No	20
A	M, 55, IIA	23	Non-Hodgkin lymphoma	Cervical	70
A†	F, 62, IIA	3	Non-Hodgkin lymphoma	No	54*
E	M, 65, IIA	51	Non-Hodgkin lymphoma	No	32
Solid tumors
A	M, 32, IA	23	Malignant melanoma	No	100
A†	F, 42, IIA	2	Breast	Mediastinal	56*
A	M, 49, IIA	44	Esophagus	Mediastinal	3*
A	M, 58, IIA	107	Lung	No	1*
A	F, 59, IIA	38	Breast	Mediastinal	44
A‡	M, 60, IIA	38	Bladder	No	9*
A	M, 64, IA	67	Leiomyosarcoma	Axillary	20*
A	M, 65, IIA	61	Colon	No	10*
E	F, 18, IIA	85	Thyroid	Mediastinal	24
E	F, 23, IIA	112	Glioma	No	3
E	F, 39, IIA	87	Breast	Mediastinal	17
E	M, 46, IIA	105	Lung	Mediastinal	7*
E	M, 46, IIIB	56	Larynx	Cervical	8*
E	M, 50, IIIB	97	Lung	Mediastinal	24*

Patient deceased.

Not counted as an event in actuarial calculation of second malignancy risk.

Patient retreated after failure to initial chemotherapy.